claim: potently neutralizing human antibodies that block sars-cov-2 receptor binding and neutralization animals
evidence_1: from a panel of monoclonal antibodies (mabs) targeting the spike (s) glycoprotein isolated from the b cells of infected subjects, we identified several mabs that exhibited potent neutralizing activity with ic50 values as low as 0.9 or 15 ng/ml in pseudovirus or wild-type ( wt ) sars-cov-2 neutralization tests, respectively.